Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global phase 2b/3 study of S-pindolol benzoate to treat patients with cachexia in Colorectal Cancer (CRC)-IMPACT programme

Next Previous
X
Search
Trial Profile

A global phase 2b/3 study of S-pindolol benzoate to treat patients with cachexia in Colorectal Cancer (CRC)-IMPACT programme

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 21 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Espindolol (Primary)
  • Indications Cachexia
  • Focus Therapeutic Use
  • Acronyms IMPACT; IMPACT CRC

    • Most Recent Events

    • 14 Nov 2024 According to an Actimed Therapeutics media release, the Company plans to dose patients in 2025.
    • 14 Nov 2024 According to an Actimed Therapeutics media release, the company announced that Professor David Ebsworth will assume the role of Executive Chairman of the company. David will work closely in partnership with CEO Robin Bhattacherjee to support the Company's fund-raising activities to finance the planned Phase 2b/3 IMPACT clinical trial programme.
    • 07 Sep 2023 According to an Actimed Therapeutics media release, Jose Garcia MD, PhD, Professor of Medicine at the University of Washington School of Medicine, Director of the Geriatric Research Educational and Clinical Centre (GRECC) at the Puget Sound Veterans Affairs Healthcare System is the US-principal investigator for the IMPACT trial programme.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top